Shots:

• The P-III YOSEMITE & RHINE studies involve assessing faricimab (6mg at personalized dosing intervals of up to 4mos. and at fixed 2mos. intervals) vs aflibercept (2mg- fixed 2mos. intervals) in 1891 patients with DME
• The P-III TENAYA & LUCERNE studies assessing faricimab (6mg administered at fixed intervals of every 2-3 & 4mos. based on an objective assessment of disease activity @20 & 24wks.) vs aflibercept in 1329 patients with nAMD
• The studies showed- i.e faricimab demonstrated non-inferior visual acuity gains and shows greater reductions in CST- thus reducing the treatment burden for patients and was well tolerated with no new safety signals identified

 ­ Ref: Roche | Image: Roche